Quantcast

Latest Hydromorphone Stories

2014-06-03 08:32:29

Multi-Tranche Financing Provides Sufficient Funding to Take KP201 Through and Beyond Potential FDA Approval and Enables KemPharm to Advance its Full Pipeline of Abuse-Deterrent Prodrugs CORALVILLE, Iowa, June 3, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has entered into a $60 million financing agreement with an investment fund managed by...

2014-05-13 16:29:25

DUBLIN, May 13, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Mallinckrodt Inc.'s Exalgo(®) (Hydromorphone Hydrochloride Extended-release Tablets 8 mg, 12 mg and 16 mg). Actavis intends to begin shipping its product shortly and believes that, under applicable Hatch Waxman rules, it may be entitled to marketing exclusivity....

2014-05-07 08:33:35

CUPERTINO, Calif., May 7, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and CEO of DURECT Corporation, will be an industry speaker at the Bay Area Prescription Drug Abuse Summit on May 7, 2014 in San Francisco. The summit is an effort to bring together senior policymakers, medical professionals, educators, local, state and federal law enforcement and the community to seek solutions to this problem and to raise awareness of the...

2014-05-01 16:32:50

CUPERTINO, Calif., May 1, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2014. Total revenues were $6.3 million and net loss was $3.6 million for the three months ended March 31, 2014 as compared to total revenues of $4.2 million and net loss of $5.2 million for the three months ended March 31, 2013. At March 31, 2014, we had cash and investments of $21.8 million, compared to cash and investments of $24.4 million at December...

2014-04-30 12:30:02

Patent Protection for KP511 Extends KemPharm's Intellectual Property Estate for Leading Franchise of Abuse-Deterrent Opioid Medications CORALVILLE, Iowa, April 30, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled, "Benzoic...

2014-04-11 08:24:52

SAN DIEGO, April 11, 2014 /PRNewswire/ -- Rampant misinformation about Zohydro(TM) ER continues to be reported by the media and echoed in Washington D.C. and some states' capitals. These inaccurate and misleading statements are often made without proper context, and are intended to be sensational, to create fear, or to generate headlines. In many instances, these statements are not supported by scientific facts or medical evidence. Let's get the facts straight Zohydro ER is the first and...

2014-04-07 08:29:44

--Questcor Shareholders Receive $30.00 in Cash and 0.897 Mallinckrodt Shares for Each Share of Questcor Common Stock They Own-- DUBLIN and ANAHEIM, Calif., April 7, 2014 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceuticals company, and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), a high-growth biopharmaceutical company, today announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction...

2014-04-03 00:22:16

SAN DIEGO, April 2, 2014 /PRNewswire/ -- We are extremely disappointed that the U.S. Drug Enforcement Administration (DEA) Administrator, as she did in a Congressional hearing today, would repeat misinformation about Zohydro(TM) ER that has been demonstrated to be false. As informed health care experts and the U.S. Food and Drug Administration have noted for the record, Zohydro ER is no more potent than any other hydrocodone medication available. The facts are clear: Zohydro ER is the same...

2014-03-28 00:23:11

SAN DIEGO, March 27, 2014 /PRNewswire/ -- We agree with Governor Deval Patrick's intention to curb the epidemic of drug abuse in Massachusetts. However, we are extremely concerned by his unprecedented action with respect to a specific FDA-approved prescription medication. We believe Governor Patrick's ban on Zohydro(TM) ER only serves to unfairly restrict patient access to the only hydrocodone pain reliever available for long-term, daily, severe chronic pain patients who are obtaining relief...

Opioids Prescriptions Increase Significantly In Emergency Rooms
2014-03-17 05:06:33

April Flowers for redOrbit.com - Your Universe Online A new study from George Washington University (GW) reports dramatic increases in opioid analgesic prescriptions, such as Percocet, Vicodin, oxycodone and Dilaudid, during emergency room visits in the US from 2001 to 2010. These findings, reported in the journal Academic Emergency Medicine, were not explained by higher visit rates for painful conditions. The visit rates only rose moderately during the study period. “This trend is...


Word of the Day
penuche
  • A fudgelike confection of brown sugar, cream or milk, and chopped nuts.
'Penuche' is a variant of 'panocha,' a coarse grade of sugar made in Mexico. 'Panocha' probably comes from the Spanish 'panoja, panocha,' ear of grain.
Related